The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's ...

In this phase 2 study, researchers explored whether fecal microbiota transplant could overcome resistance to immune checkpoint inhibition.

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens. The Food and Drug Administration (FDA) has granted accelerated approval to Bizengri ® ...

Researchers have mapped lung cancer "neighborhoods", finding that cell metabolism is key for determining immunotherapy ...

A retrospective study finds that more than one third of patients with stage I-IIIA non-small cell lung cancer do not undergo ...

A meta-analysis of more than 20 phase 3 trials found no clear survival differences by sex or age in metastatic NSCLC but ...

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

Researchers headed by a team at Keck Medicine of USC have found that corticosteroids, which are commonly prescribed to non-small cell lung cancer (NSCLC) patients to alleviate cancer-related symptoms, ...

A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...